SHC
Sotera Health Company
$17.93
+1.64% 2026-10-20
Health CareS&P 400
SHCSPY
1W
-1.5%
1M
-4.3%
3M
+3.0%
6M
+12.3%
YTD
+1.6%
1Y
+7.3%
Live chart
Loading live chart…
Grades vs sector
Momentum41st pct in sectorC
Momentum
41st pct in sector
12-1 return: +11.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth53rd pct in sectorC+
Growth
53rd pct in sector
Revenue growth (YoY): +9.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value64th pct in sectorB-
Value
64th pct in sector
Forward E/P: 6.0% · EBITDA/EV: 8.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability76th pct in sectorB+
Profitability
76th pct in sector
Profit margin: +13.4% · Return on equity: +27.8%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More news2 Profitable Stocks to Keep an Eye On and 1 We Question
StockStory · Oct 19
Sotera Health Shares Fall After JPMorgan Downgrade
MT Newswires · Oct 14
JPMorgan Downgrades Sotera Health to Underweight From Neutral, Price Target is $17
MT Newswires · Oct 14
Is Sotera Health (SHC) Still A Bargain After A 35% Gain?
Simply Wall St. · Oct 09
Here’s Why Sotera Health Company (SHC) Surges 25% in Q2
Insider Monkey · Sep 15
Key stats
Market cap$5.1B
P/E (trailing)31.5
P/E (forward)16.7
52-week range13.09 – 19.85
Revenue growth (YoY, latest qtr)+9.2%
Dividend yield0.00%
Analyst consensusBuy (9)
Mean price target$22.61 (+26%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Looks expensive
Model read-out from the numbers below, not advice. Score -3 (DCF counts double).
▼DCF (base case)below the price by 108%
•Forward P/E vs sector16.7x vs median 17.6x
•Piotroski F-score6/9
▼Altman Z1.8 (distress)
▼Net debt / EBITDA4.5x
▲Analyst target+26% (9 analysts)
Discounted cash flow
Bear
$-3
-116%
growth 2% · disc. 14.0% · term. 2.0%
Base
$-1
-108%
growth 7% · disc. 13.0% · term. 2.5%
Bull
$0
-98%
growth 10% · disc. 12.0% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 30% a year for 10 years.
Implied
+30%/yr
FCF, last 3 yrs
+16%/yr
FCF, last 5 yrs
+17%/yr
Revenue, last 3 yrs
+5%/yr
Revenue, last 5 yrs
+7%/yr
Same inputs as the DCF above: trailing free cash flow 0.1B, 13.0% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.85 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
pricier
sector median 29.9× · 53rd pct
31.5×pricier
Forward P/E
cheaper
sector median 17.6× · 45th pct
16.7×cheaper
EV / EBITDA
pricier
sector median 15.8× · 59th pct
17.6×pricier
Price / sales
pricier
sector median 3.1× · 64th pct
4.2×pricier
Price / book
pricier
sector median 3.5× · 81st pct
7.7×pricier
FCF yield
pricier
sector median 4.1% · 25th pct
2.2%pricier
Forward EPS $1.07 vs trailing $0.57 (+89% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
55.0%
Operating margin
24.5%
FCF margin
9.3%
Net margin
13.4%
Return on equity
24.6%
Return on invested capital
7.9%
Net debt / EBITDA
4.5×
Current ratio
2.8×
Interest cover
–
Cash conversion (OCF/NI)
1.8×
Piotroski F-score 6/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✓ Gross margin improved✗ Asset turnover improved
Altman Z-score 1.8 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$23
+26%
Analysts
9
Buy
Range
$17–$25
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $1.2B | $77.9M | $149.2M |
| 2024 | $1.1B | $44.4M | $45.1M |
| 2023 | $1.0B | $51.4M | $-362.7M |
| 2022 | $1.0B | $-233.6M | $95.6M |
| 2021 | $931.5M | $116.9M | $179.4M |
| 2020 | $818.2M | $-38.6M | $67.1M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +5.1%.
Earnings
Next report: 2026-11-03 · before open · EPS est 0.27
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | 0.24 | 0.26 | +8.7% |
| 2026-05-05 | 0.17 | 0.18 | +3.4% |
| 2026-02-24 | 0.24 | 0.26 | +7.0% |
| 2025-11-04 | 0.22 | 0.26 | +19.1% |
| 2025-08-08 | 0.17 | 0.20 | +15.9% |
| 2025-05-01 | 0.12 | 0.14 | +14.9% |
| 2025-02-27 | 0.20 | 0.21 | +4.0% |
| 2024-11-05 | 0.18 | 0.17 | -7.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $321.4M | +9.2% |
| 2026-03-31 | $280.0M | – |
| 2025-12-31 | $303.4M | – |
| 2025-09-30 | $311.3M | – |
| 2025-06-30 | $294.3M | – |
Analyst actions
JP Morgan
PT $17
2026-10-14 · down
Neutral → UnderweightPT $17
Citigroup
PT $25
2026-08-07 · main
Buy → BuyPT $25
Barclays
PT $22
2026-08-07 · main
Overweight → OverweightPT $22
Piper Sandler
PT $25
2026-08-07 · reit
Overweight → OverweightPT $25
JP Morgan
PT $18
2026-08-07 · main
Neutral → NeutralPT $18
Barclays
PT $19
2026-06-24 · main
Overweight → OverweightPT $19
Insider trades
Petras Michael B. Jr.
$5.4M
Director, Executive Chairman · 2026-08-17
SELL$5.4M
Petras Michael B. Jr.
$15.7M
Director, Executive Chairman · 2026-08-17
SELL$15.7M
Rutz Michael P
$2.8M
President of Sterigenics · 2026-08-07
SELL$2.8M
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:03:28 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.